secondary endpoints

Related by string. secondary endpoint * SECONDARY . Secon dary . Secondary : Secondary School . Secondary Schools . Secondary Offering . Secondary Education / Endpoint . Endpoints . EndPoint : Secondary endpoints include . primary efficacy endpoint . secondary efficacy endpoints * Secondary endpoints included . specified secondary endpoints . Key secondary endpoints *

Related by context. All words. (Click for frequent words.) 81 secondary endpoint 81 secondary efficacy endpoints 80 primary endpoint 76 primary endpoints 76 primary efficacy endpoint 75 efficacy endpoints 73 Secondary endpoints 70 primary efficacy endpoints 68 Secondary efficacy endpoints 66 composite endpoint 66 demonstrated statistically significant 66 Secondary endpoints included 65 efficacy endpoint 65 clinical endpoints 64 secondary efficacy endpoint 64 prespecified 64 prospectively defined 64 statistically significant improvement 63 pharmacodynamic 63 non inferiority 63 Primary endpoints 63 achieved statistical significance 61 exploratory endpoints 61 Secondary endpoints include 60 pharmacodynamic endpoints 60 evaluable 60 lipid parameters 60 statistically significant reduction 59 tolerability 59 ATACAND 59 achieve statistical significance 59 bosentan 59 noninferiority 58 desvenlafaxine succinate 58 clinically meaningful 58 placebo 58 endoscopic remission 58 Efficacy endpoints 58 subgroup analyzes 58 timepoint 58 patients evaluable 58 metabolic parameters 57 evaluable patients 57 active comparator 57 teriflunomide 57 mg dose 57 prespecified secondary 57 Montgomery Asberg Depression 57 free survival PFS 57 elagolix 57 retinal thickness 57 p = #.# [002] 57 statistical significance 57 Endpoints 57 mcg QD 57 HBeAg positive patients 57 cytogenetic response 57 placebo p 57 Events MACE 57 Psoriasis Area 56 CIMZIA TM 56 nonrandomized 56 clinically meaningful improvements 56 endpoints 56 pharmacokinetic parameters 56 pharmacokinetics PK 56 Rating Scale MADRS 56 statistically significant 56 nab paclitaxel 56 Negative Syndrome 56 progression TTP 56 dosage regimens 56 TRITON TIMI 56 #mg BID [003] 55 trospium 55 viral kinetics 55 statistically significant differences 55 HBeAg negative patients 55 monotherapy 55 tapentadol ER 55 TLUS 55 morphometric vertebral fractures 55 MEND CABG 55 GERD symptom 55 trough FEV1 55 Alzheimer Disease Assessment 55 viral kinetic 55 complete cytogenetic 55 Phase 2b study 55 alicaforsen enema 55 evaluating REVLIMID 55 placebo controlled 55 dosing regimens 55 placebo p = 55 fosbretabulin 55 spontaneous bowel movements 55 mcg BID 55 FOLPI 55 virologic response 55 ACR# [002] 55 mg BID 55 #mg QD [001] 55 ACTEMRA 55 ACTEMRA TM 55 plus ribavirin 55 virologic 55 demonstrated clinically meaningful 55 lopinavir r 55 STRIDE PD 55 HAMD 55 subanalysis 55 subscales 55 trials RCTs 55 placebo controlled clinical trials 55 placebo controlled clinical 55 dosing cohorts 55 LEVADEX 54 ACR# response 54 EURIDIS 54 clinically relevant 54 treatment emergent adverse 54 postdose 54 headache nasopharyngitis 54 apremilast 54 ALVESCO 54 p = #.# [004] 54 tipranavir 54 4mg/kg 54 peginterferon alfa 2b 54 prospective randomized controlled 54 INCB# [003] 54 CIMZIA TM certolizumab pegol 54 RE LY ® 54 mg QD 54 docetaxel 54 plus methotrexate 54 GAMMAGARD 54 pharmacodynamic PD 54 efficacy tolerability 54 liver histology 54 tanespimycin 54 oxycodone CR 54 achieved ACR# 54 clinically meaningful improvement 54 Crohn Disease Activity 54 sustained virologic response 54 REYATAZ r 54 etanercept 54 HCV RESPOND 2 54 NLX P# 54 Azixa 54 irbesartan 54 1mg dose 54 chlorambucil 54 dose limiting toxicities 54 posaconazole 54 PREZISTA r 54 Free Survival PFS 54 PRECiSE 54 pharmacokinetic PK 54 nausea photophobia 54 undetectable HBV DNA 54 tolvaptan 54 analgesic efficacy 54 ABC/3TC 54 dacetuzumab 54 APTIVUS r 53 oral FTY# 53 Androxal TM 53 HAM D# 53 SVR# 53 BENICAR HCT 53 abdominal pain abdominal discomfort 53 ADAS Cog 53 SPIRIT FIRST 53 tipranavir r 53 Efficacy 53 angiographic outcomes 53 solifenacin 53 nonresponders 53 CIMZIA ™ 53 randomized Phase 2b 53 melphalan prednisone 53 eplerenone 53 certolizumab pegol 53 Xanafide 53 RECIST Response Evaluation Criteria 53 tumor progression TTP 53 TEAEs 53 Thrombolysis 53 adalimumab 53 median PFS 53 pain palliation 53 macrovascular events 53 CARE HF 53 rALLy trial 53 pharmacokinetic 53 pegylated interferon alfa 2b 53 catheter occlusion 53 mucosal healing 53 BENICAR 53 certolizumab 53 Scale EDSS 53 limiting toxicity 53 Phase Ib clinical 53 SCH # 53 Traficet EN 53 comparator arm 53 #mg BID [001] 53 Phase 1b 53 P = .# 53 ritonavir boosted 53 TAXUS Stent 53 surrogate endpoint 53 baminercept 53 cardiovascular morbidity 53 CANCIDAS 53 mcg kg 53 dose regimens 53 Kaplan Meier analysis 53 symptom severity 53 Scale PANSS 53 partial remissions 53 dose cohorts 53 pharmacodynamic effects 53 RAPAFLO R 53 tolerability profiles 53 Montgomery Åsberg Depression 53 rolofylline 53 LEXIVA r 53 genotypic resistance 53 clevidipine 53 randomized 53 splenectomized patients 53 HbA1c levels 53 rosuvastatin #mg 53 CSBM 53 APPRAISE 53 abciximab 53 elotuzumab 53 ascending doses 53 CRp 52 glufosfamide 52 INC# 52 post hoc 52 peginterferon 52 mg kg dose 52 ENDEAVOR II 52 undetectable HCV RNA 52 galiximab 52 CCyR 52 SABCS 52 plus dexamethasone 52 KRAS status 52 Index CDAI 52 Key secondary endpoints 52 IIIa inhibitor 52 p = 52 ADCS CGIC 52 serologically active patients 52 MEND CABG II 52 Phase 2a trial 52 EVEREST II 52 iclaprim 52 TIMI 52 #mg/day [001] 52 edoxaban 52 MADRS 52 serum phosphorous 52 iniparib 52 daily Infergen 52 insulin detemir 52 prucalopride 52 HDRS 52 laboratory abnormalities 52 randomized double 52 sirolimus eluting stents 52 lopinavir r arm 52 INCB# [001] 52 remission CR 52 GOUT 52 nonfatal MI 52 ADAS cog 52 pharmacokinetic PK profile 52 AEGR 52 FOLFIRI 52 XIENCE V PROMUS Stent 52 events AEs 52 SYNTAX trial 52 crizotinib PF # 52 RoACTEMRA 52 Unified Parkinson Disease 52 reach statistical significance 52 6R BH4 52 events MACE 52 efficacy 52 oral rivaroxaban 52 virological response 52 favorable pharmacokinetic profile 52 INCB# [002] 52 sirolimus eluting stent 52 sunitinib 52 CDAI 52 NEVO ™ 52 mcg albinterferon alfa 2b 52 adjuvant GIST 52 tolterodine ER 52 #mg QD [002] 52 mg kg 52 prognostic factors 52 MoxDuo TM IR 52 everolimus eluting stents 52 FOLFOX6 52 refractory AML 52 pharmacokinetics 52 randomized controlled 52 double blind placebo 52 neurologic progression 52 febrile neutropenia 52 safinamide 52 Neuropsychiatric Inventory NPI 52 concomitant medications 52 ribavirin RBV 52 FOLFOX 52 OAB symptoms 52 tolerability pharmacokinetics 52 NATRECOR R 52 NEVO RES 52 dyspnea 52 sUA 52 Tiotropium 52 ularitide 52 cilostazol 52 NYHA functional class 52 phase IIIb 52 PASI scores 52 TMC# C# 52 Pegasys ® 52 plasma pharmacokinetics 52 prospective randomized multicenter 52 Baseline characteristics 52 HCV SPRINT 52 pharmacodynamic parameters 52 Phase 2a clinical 52 #mg/m# [002] 52 binary restenosis 52 pertuzumab 52 rapid virologic response 52 Brief Psychiatric 52 alvimopan 52 ACR# ACR# 52 pramlintide metreleptin combination 51 primary hypercholesterolemia 51 PRIMO CABG2 51 fasting plasma glucose 51 docetaxel chemotherapy 51 placebo controlled Phase III 51 antipsychotic efficacy 51 placebo controlled studies 51 Exelixis compounds 51 FEV1 51 tiotropium 51 μg dose 51 #μg [002] 51 AZILECT R 51 posttreatment 51 PANSS 51 ascending dose 51 CTEPH 51 hypoglycemic events 51 bicifadine 51 bortezomib 51 CSBMs 51 randomized #:#:# 51 acute coronary syndromes ACS 51 LPV r 51 DAPT 51 prospective multicenter randomized 51 low dose cytarabine 51 Solid Tumors criteria 51 HAQ DI 51 lipid lowering agents 51 tolerability profile 51 FOLFOX4 51 intermittent dosing 51 riociguat 51 Doxil ® 51 evaluable subjects 51 inflammatory biomarkers 51 double blinded randomized 51 hemodynamic measurements 51 Phase 2b clinical 51 bivalirudin 51 #mg dose [003] 51 HIV RNA 51 Major Adverse Cardiac 51 PS# [001] 51 incontinence episodes 51 CYPHER ® Stent 51 CALGB # [001] 51 pramipexole 51 acutely decompensated congestive heart 51 EMBLEM TM 51 aclidinium 51 velafermin 51 comorbid conditions 51 calcineurin inhibitor 51 sustained virological response 51 indiplon capsules 51 mg doses 51 Hyphanox 51 timepoints 51 Phase IIIb 51 colesevelam HCl 51 covariate 51 n = 51 BRIM2 51 SPIRIT III 51 Phase Ib study 51 placebo controlled Phase 51 virologic failure 51 #mg BID [002] 51 Response Evaluation Criteria 51 fosamprenavir 51 candesartan cilexetil 51 rotigotine 51 LVEF 51 Adalimumab 51 pioglitazone 51 oral diclofenac 51 nasal symptom 51 valsartan 51 NATRECOR ® 51 adefovir 51 XGEVA 51 RECIST criteria 51 IPSS 51 ARB telmisartan 51 FOSRENOL ® 51 docetaxel Taxotere ® 51 MADRS score 51 glycosylated hemoglobin levels 51 ONTARGET 51 EGFR HER2 51 recurrent glioblastoma multiforme 51 VIRAMUNE 51 atrasentan 51 coadministration 51 RE SURGE 51 clodronate 51 nonsignificant 51 Thal Dex 51 ANCHOR trial 51 carboplatin paclitaxel 51 REMICADE ® 51 MAP# 51 brivaracetam 51 mitoxantrone 51 ARCOXIA 51 gout flares 51 SGRQ 51 ACCORD Lipid 51 budesonide MMX 51 orBec 51 virologic responses 51 plasma concentrations 51 demonstrated antitumor activity 51 Acute Ischemic Stroke 51 Monotherapy 51 varespladib 51 aldosterone antagonist 51 ADX# 51 enoximone 51 ENDEAVOR III 51 ruboxistaurin 51 plus COPEGUS 51 neoadjuvant 51 inflammatory lesions 51 Dapagliflozin 51 mycophenolate mofetil 51 safety tolerability 51 Phase IIB 51 Chemophase 51 SBMs 51 VELCADE melphalan 51 pharmacokinetic equivalence 51 vicriviroc 51 paclitaxel eluting stents 51 TAXUS VI 51 prednisone prednisolone plus 51 Pain Intensity 51 HORIZONS AMI trial 51 budesonide 51 celgosivir 51 imatinib 51 phase IIb clinical 51 administered subcutaneously 51 SIMPADICO 51 MACCE 51 clinically meaningful differences 51 Ceplene/IL-2 51 ponatinib 51 mapatumumab 51 KRN# 51 levosimendan 51 mITT population 50 pegylated liposomal doxorubicin 50 EFAPROXYN 50 APTIVUS 50 Phase 2b 50 denufosol 50 SPIRIT IV 50 histologies 50 aliskiren 50 pharmacokinetics pharmacodynamics 50 quetiapine XR 50 HRQL 50 OMNARIS HFA 50 infliximab 50 Ocrelizumab 50 randomized discontinuation trial 50 aflibercept 50 CLARITY study 50 Randomized Evaluation 50 TDF FTC 50 Phase Ib II 50 HbA1C levels 50 statistically significant p 50 peginterferon alfa 2a 50 Phase IIa clinical 50 placebo controlled randomized 50 double blinded placebo 50 serum phosphorus 50 F FDG PET 50 SYMMETRY trial 50 randomized multicenter 50 pharmacokinetic profiles 50 subscale scores 50 vidofludimus 50 Severity Index PASI 50 AZD# 50 tasimelteon 50 ARIXTRA 50 Pharmacokinetics PK 50 #:# randomization 50 prespecified criteria 50 discontinuations due 50 docetaxel Taxotere 50 fluoropyrimidine 50 inhaled iloprost 50 Amrubicin 50 Pharmacokinetic 50 VAPRISOL 50 romiplostim 50 PSN# [002] 50 interferon gamma 1b 50 CR nPR 50 abiraterone acetate 50 relapsed MM 50 randomized placebo controlled 50 Phase Ib 50 hemodynamic parameters 50 phase Ib 50 tumor shrinkage 50 phonophobia 50 CRESTOR #mg 50 inhibitor RG# 50 hematologic 50 complete remissions 50 EVIZON 50 #.#/#.# mmHg [001] 50 infarct size 50 ongoing Phase 1b 50 response CCyR 50 eptifibatide 50 R# #mg BID 50 ataluren 50 Solid Tumors 50 Virologic 50 mg/m2 dose 50 Tarceva TM 50 Phase 2a 50 Taxotere R 50 Aptivus ® 50 covariates 50 linaclotide treated 50 Phase IIa 50 QNEXA 50 dose titration 50 Fludara 50 LEXIVA 50 RLS symptoms 50 label dose titration 50 phase IIa 50 Expanded Disability Status 50 belimumab 50 PCWP 50 adalimumab Humira 50 DexaSite 50 zolmitriptan 50 echocardiographic parameters 50 Triolex 50 Phase IIa trial 50 DAS# [002] 50 Microplasmin 50 SPIRIVA HandiHaler 50 temsirolimus 50 alpha 2a 50 peginterferon alfa 2a #KD 50 mesalamine granules 50 endothelin receptor antagonists 50 abacavir lamivudine 50 β blockers 50 diabetic neuropathic pain 50 chemoradiation 50 thromboembolic events 50 surrogate markers 50 Virulizin ® 50 serum concentrations 50 ibandronate 50 achieved PASI 50 Median progression 50 Phase III placebo controlled 50 multicentre randomized 50 preoperatively 50 Pharmacokinetic parameters 50 AzaSite Plus 50 LHRH antagonists 50 icatibant 50 non selective NSAIDs 50 unresectable HCC 50 L PPDS 50 therapeutic regimens 50 Proellex TM 50 AGILECT R 50 randomized controlled clinical 50 bortezomib refractory 50 eculizumab 50 ACR Pedi 50 ruxolitinib 50 erlotinib Tarceva ® 50 UPDRS 50 Ostarine 50 chills fever headache 50 squalamine 50 octreotide 50 Dacogen injection 50 Panzem R NCD 50 Phase #b/#a clinical 50 symptomatic VTE 50 univariate analysis 50 Tekamlo 50 imatinib therapy 50 vismodegib 50 antihypertensive therapy 50 DSMB 50 substudy 50 nicardipine 50 endoscopic gastric ulcers 50 fasting plasma glucose FPG 50 placebo controlled trials 50 Candesartan 50 cEVR 50 adjunctive placebo 50 Lupuzor ™ 50 recurrent GBM 50 QD dosing 50 methotrexate monotherapy 50 achieve sustained virologic 50 tirofiban 50 dimebon 50 mg TID 50 cediranib 50 XL# XL# XL# XL# 50 RCTs 50 candesartan 50 8mg/kg 50 IR prednisone 50 CHAMPION PLATFORM 50 EDEMA3 trial 50 Score IPSS 50 beclomethasone dipropionate 50 LibiGel Phase III 50 International Prostate Symptom 50 IOP lowering 50 Contrave# 50 Onbrez Breezhaler 50 custirsen 50 antitumor activity 50 oral Xeloda 50 phase IIb 50 LIALDA 50 Phase IIb clinical 50 ischemic cardiomyopathy 50 antihypertensive agents 50 vasomotor symptoms 50 clinically meaningful reductions 50 PEG Intron 50 50 multicenter randomized controlled 50 nasopharyngitis 50 5-FU/LV 50 zileuton 50 Ereska 50 PROMACTA 50 paricalcitol 50 antiviral efficacy 50 TAXUS ATLAS 50 systemic embolism 50 PEGylated interferon beta 1a 50 mg/m2 50 Pivotal Phase 50 tolterodine 50 DLTs 50 IBDQ 50 coronary stenosis 50 LUNESTA 50 dose escalation phase 50 Entereg R 50 PREZISTA r arm 50 postintervention 50 prospective multicentre 50 Cleviprex TM clevidipine 50 goserelin 50 serum phosphate levels 50 CCX# 50 Elocalcitol 50 death reinfarction 50 hemoglobin A1c HbA1c 50 XIENCE V demonstrated 50 PEGylated anti 50 metastatic castration resistant 50 liposomal doxorubicin 49 locoregional recurrence 49 abatacept 49 HGS ETR2 49 target vessel revascularization 49 ADAGIO study 49 PRT# 49 tolerated dose MTD 49 Tolerability 49 specific antigen PSA 49 Subgroup analyzes 49 montelukast 49 receiving golimumab 49 Taxotere ® 49 TYSABRI treated 49 platinum refractory 49 Primary Endpoint 49 mcg doses 49 #mg/day [002] 49 GSK# [001] 49 ancrod 49 KOMBIGLYZE XR 49 lanthanum carbonate 49 posttransplant 49 tumor necrosis 49 HCV RNA 49 CAMMS# 49 gefitinib 49 diameter stenosis 49 renal function 49 QoL 49 ramipril 49 EDEMA4 trial 49 pharmacodynamics PD 49 zonisamide SR 49 mitoxantrone plus 49 neratinib 49 paclitaxel carboplatin 49 definite stent thrombosis 49 eculizumab therapy 49 ASCEND HF 49 lipid lowering therapies 49 ADCS ADL 49 oblimersen 49 plus gemcitabine 49 dyslipidaemia 49 WOMAC pain 49 salmeterol fluticasone 49 ENDEAVOR IV 49 TMC# r 49 tocilizumab 49 EXPAREL ™ 49 anti angiogenic agents 49 Meta analyzes 49 baseline HbA1c 49 dosing cohort 49 YMRS 49 cerebrovascular events 49 briakinumab 49 ciclesonide 49 serum urate 49 dose cohort 49 epoetin alpha 49 pegylated interferon 49 achieved sustained virologic 49 oral prodrug 49 Phase IIb 49 randomized Phase III 49 insulin glargine 49 UPDRS motor 49 CA4P 49 dacarbazine 49 trastuzumab 49 dacarbazine chemotherapy 49 Oral Fingolimod 49 Empatic 49 ExTRACT TIMI 49 sipuleucel T 49 heavily pretreated patients 49 acute bronchospasm 49 FDA defined valvulopathy 49 darunavir ritonavir 49 cangrelor 49 randomized clinical trials 49 TNSS 49 Cloretazine 49 nonclinical studies 49 pharmacokinetic profile 49 OPT CHF 49 AZILECT 49 statistically significant p = 49 multicenter Phase III 49 p = NS 49 #mg/m# [001] 49 BROVANA 49 severe exacerbations 49 Atacand 49 RRMS patients 49 pharmacodynamic profiles 49 DAS# CRP 49 GEM OS1 49 valopicitabine 49 nucleoside naive patients 49 APTIVUS R 49 torsemide ER 49 SSRI citalopram 49 EBMT criteria 49 mcg mL 49 mg ustekinumab 49 selective modulator 49 fallopian tube cancers 49 immunosuppressive agents 49 COMFORT II 49 micafungin 49 systolic BP 49 Clolar ® 49 allopurinol 49 pharmacokinetic studies 49 lintuzumab 49 PXD# 49 apolipoprotein B 49 atazanavir ritonavir 49 CIMZIA R 49 sumatriptan naproxen sodium 49 Teriflunomide 49 Phase #/#a 49 QTc prolongation 49 IPX# 49 Initiated Phase 49 Zemplar Capsules 49 randomization 49 metastatic GIST 49 almorexant 49 cannabinor 49 mRCC 49 annualized relapse 49 phase IIa clinical 49 novel VDA molecule 49 FOSRENOL R 49 CHAMPION PCI 49 creatinine clearance 49 nausea somnolence 49 statistical significance p 49 complete cytogenetic response 49 discontinuations 49 calcineurin inhibitors 49 log# IU mL 49 esomeprazole 49 Long Term Efficacy 49 multicenter randomized 49 visilizumab 49 Tasimelteon 49 ULORIC 49 MCyR 49 enzastaurin 49 CDAI score 49 relapsing multiple sclerosis 49 adjuvant therapies 49 bosutinib 49 NP2 Enkephalin 49 telaprevir dosed 49 decitabine 49 ticagrelor 49 REMINYL ® 49 maximally tolerated dose 49 periprocedural 49 MIST II 49 nadolol 49 lamotrigine 49 Capesaris 49 TNF antagonists 49 risperidone Risperdal 49 bronchodilation 49 glycoprotein IIb IIIa inhibitor 49 Subgroup analysis 49 pulmonary exacerbations 49 axitinib 49 safety tolerability pharmacokinetic 49 Phase Ia 49 Main Outcome Measures 49 hyperoxaluria 49 febuxostat 49 Pharmacokinetic PK 49 BMS # 49 evaluating Actimmune 49 HbA 1c 49 INVEGA ® 49 methacholine challenge 49 cethromycin 49 multicenter placebo controlled 49 graft dysfunction 49 OADs 49 olmesartan 49 #mg/kg [002] 49 oral levofloxacin 49 statistically significant superiority 49 Aurexis 49 AVOREN 49 PRE SURGE 49 serologically active SLE 49 TELCYTA 49 plasma uric acid 49 ACE inhibitor ramipril 49 μg kg 49 multicenter Phase 49 urate lowering 49 safety tolerability pharmacokinetics 49 CYT# potent vascular disrupting 49 HbA1c 49 YONDELIS 49 Pivotal Phase III 49 dosing schedules 49 EDEMA3 49 telcagepant 49 pharmacokinetic PK study 49 unblinded 49 Symptom severity 49 bezafibrate 49 dasatinib 49 Phase 1a 49 CoFactor 49 HMG CoA reductase inhibitors 49 myocardial infarction stroke 49 relapsers 49 davunetide intranasal AL 49 vandetanib 49 GFT# 49 Monitoring ABPM 49 cariprazine 49 Phase 1b trial 49 PEG Interferon lambda 49 GLIADEL R Wafer 49 CI -#.# 49 ONGLYZA 49 log# 49 imetelstat 49 oral antidiabetic agents 49 RSD# oral 49 WARNINGS Myopathy Rhabdomyolysis 49 multicenter randomized double 49 calculated creatinine clearance 49 AVADO 49 ToGA 49 glatiramer acetate 49 BARACLUDE r 49 PIX# [002] 49 evaluating tivozanib 49 Phase 1a clinical 49 randomized clinical 49 sirolimus 49 actigraphy 49 ug kg 49 tecarfarin 49 incidence ≥ 49 multiple ascending dose 49 Aflibercept 49 pegylated interferon peg IFN 49 Study GL# 49 pharmacologic 49 apnea hypopnea index 49 Dyloject TM 49 Polyp Prevention Trial 49 YERVOY 48 NO# [002] 48 nucleoside reverse transcriptase inhibitor 48 peg interferon 48 CorVue ™

Back to home page